There is a real cannabis-based medicine route in one specific multiple sclerosis context. NICE recommends a 4-week trial of THC:CBD spray for moderate to severe spasticity in adults with MS when other pharmacological treatments for spasticity have not been effective and the NICE conditions are met.
That is narrower than many people expect. It is about MS spasticity, not every MS symptom. It is about a specific THC:CBD spray, often known by the brand name Sativex, not any cannabis product. It also does not mean that every person with MS will routinely receive medical cannabis. If someone is exploring the wider private route, a checker or first conversation can only suggest whether they may qualify; the final decision still depends on records, previous treatments, risks and specialist assessment.
This guide is not medical advice. MS spasticity, pain, mobility, fatigue, bladder symptoms, mood, sleep, medicines, side effects and impairment all need proper clinical review. If you are trying to understand the wider UK route, start with the MCPH patient guide. For safety background, read medical cannabis side effects and THC side effects and impairment.
What MS spasticity means
Multiple sclerosis can affect the brain and spinal cord. NHS information explains that MS symptoms vary between people and can include muscle cramps, spasms and stiffness.
Spasticity is a specific symptom area. It can affect movement, posture, comfort, sleep, transfers, washing, dressing and daily life. It can also be made worse by other factors, such as infection, bladder or bowel problems, pressure ulcers, poor positioning, posture issues or pain.
That matters because a good spasticity assessment is not simply a matter of adding another medicine. NICE’s MS guideline says clinicians should assess factors that might worsen spasticity and discuss the balance between benefits and harms of treatment. For some people, reducing spasticity may help comfort or function. For others, some stiffness may be part of how they stand, transfer or maintain posture, so treatment choices need care.
What NICE says about THC:CBD spray
NICE NG144 recommends offering a 4-week trial of THC:CBD spray to treat moderate to severe spasticity in adults with MS if other pharmacological treatments for spasticity are not effective and the pay-for-responders scheme applies.
After the trial, NICE says THC:CBD spray should continue only if the person has at least a 20% reduction in spasticity-related symptoms on a 0 to 10 patient-reported rating scale.
NICE also says treatment should be initiated and supervised by a physician with specialist expertise in treating spasticity due to MS, in line with the medicine’s marketing authorisation.
The key points are:
- adult MS spasticity
- moderate to severe symptoms
- other pharmacological spasticity treatments not effective
- a 4-week trial
- response measured after the trial
- specialist initiation and supervision
That is a defined clinical pathway, not a broad statement that cannabis-based medicines are recommended for MS generally.
How NICE NG220 fits in
NICE NG220 is the wider MS management guideline. It says clinicians should suspect spasticity when a person with MS has symptoms such as increased muscle tone, spasms, stiffness, pain, clonus or functional problems.
It also places THC:CBD spray after other steps. NICE discusses assessing factors that worsen spasticity, setting treatment goals, considering oral baclofen first line for suitable patients, considering gabapentin second line where baclofen is not tolerated or does not give enough relief, and referring to a multidisciplinary spasticity team where impairment remains significant and initial treatments are unsuccessful.
For THC:CBD spray, NG220 points back to NG144. This keeps the cannabis-based medicine recommendation narrow and connected to specialist MS spasticity management.
Sativex, nabiximols and broader cannabis products are not the same discussion
NHS information describes nabiximols, also known as Sativex, as a cannabis-based medicine sprayed into the mouth. It is licensed in the UK for adults with MS-related muscle spasticity that has not improved with other treatments.
NHS England also says that, for MS spasticity, licensed THC:CBD spray should be used over unlicensed cannabis-based products for medical use.
That difference matters. A licensed THC:CBD spray used under a NICE spasticity recommendation is not the same as a broader private-clinic discussion about unlicensed cannabis-based medicinal products. A private specialist may assess individual patients under professional rules, but the existence of the NICE Sativex pathway should not be stretched into a claim that MS routinely leads to private cannabis prescribing.
If an article, advert or clinic page makes MS sound like a simple access category, it needs careful checking. The better question is: what symptom is being assessed, what treatments have already been tried, what are the risks, and which clinician is responsible for the decision?
What the MS Society says
The MS Society is important patient context because it is a major UK MS charity and has campaigned on access to Sativex. Its public information says one cannabis-based medicine, Sativex, is licensed in the UK to treat MS spasticity. It also explains that Sativex is approved for NHS use across the UK for some people with moderate to severe spasticity when other treatments have not worked.
That support is still specific. The MS Society does not present cannabis-based medicines as a general answer for every MS symptom. It explains that NICE looked at licensed and unlicensed cannabis-based products for MS and only recommended Sativex for treating MS spasticity. It also separates prescribed cannabis-based medicines from CBD oils sold as food supplements.
The charity also gives useful access context. Even where Sativex is approved, people may still face local barriers because NHS bodies or local prescribers do not always fund or provide it consistently. For patients, that helps explain why the route can feel confusing: the issue is not only whether the medicine exists, but whether the right patient can actually access it through the right clinical service.
For MCPH, the practical takeaway is:
- MS Society support strengthens the case for explaining the Sativex pathway clearly
- it does not turn MS into automatic cannabis eligibility
- it helps patients understand why access can feel confusing even where NICE supports a narrow use
- it reinforces the need to separate licensed Sativex for MS spasticity from broader private medical cannabis discussions
What patients can prepare for a spasticity conversation
Useful preparation is practical. Patients can describe the spasticity symptoms in plain language, note what makes them worse, list treatments already tried for spasticity and explain why they helped, failed or caused problems.
Relevant letters from neurology, rehabilitation, physiotherapy, occupational therapy or MS nursing teams may help. So can a current medicines list, including prescribed medicines, over-the-counter products, supplements, CBD products and any non-prescribed cannabis use.
It is also worth being honest about mood, cognition, previous adverse cannabis reactions, sleep, falls, driving, work and caring responsibilities. This is not about asking for a particular product. It is about giving an MS clinician or specialist prescriber enough information to judge the safest next step.
Safety issues to keep visible
THC-containing medicines can cause side effects and impairment. The NHS medical cannabis page lists possible side effects including dizziness, tiredness, mood or behavioural change, hallucinations and suicidal thoughts. It also notes that CBD and THC can affect how other medicines work.
For MS patients, that can matter because treatment plans may already include medicines for spasticity, pain, sleep, bladder symptoms, mood, seizures or other conditions. Falls risk, fatigue, cognition, driving, work, caring responsibilities and mental health history may also affect the assessment.
If driving is part of your life, read MCPH’s guide to medical cannabis and driving in the UK for general context. Do not treat any guide as personal driving clearance.
If you are trying to understand the language around THC and CBD, read THC:CBD ratios explained. Product choice, dose, route and monitoring still sit with the prescriber.
What this means in plain English
There is a real NICE-backed cannabis-based medicine context in MS, but it is specific. It is THC:CBD spray for moderate to severe MS spasticity in adults, after other pharmacological treatments have not been effective, with a measured trial and specialist supervision.
That should give patients clarity, not false certainty. If you have MS and spasticity, it may be reasonable to ask your MS team or a specialist prescriber how your symptoms, previous treatments and risks fit with current guidance. It is not reasonable for any website to imply that MS on its own makes cannabis-based treatment routine.
FAQ
Does NICE recommend medical cannabis for MS?
NICE recommends a specific THC:CBD spray trial for moderate to severe spasticity in adults with MS when other pharmacological treatments are not effective and the NICE conditions are met. That is not a general recommendation for all MS symptoms.
Does the MS Society support cannabis-based medicines for MS?
The MS Society supports clearer access to Sativex for eligible people with MS spasticity and provides patient information on cannabis and MS. Its support is focused on the licensed Sativex pathway and access barriers, not a blanket claim that every person with MS should receive cannabis-based treatment.
Is Sativex the same as any cannabis oil or flower?
No. Sativex, or nabiximols, is a specific licensed THC:CBD spray. NICE’s MS spasticity recommendation should not be treated as a recommendation for any cannabis product.
Does having MS mean I may qualify for medical cannabis?
MS alone should not be framed as routine access. The relevant NICE context is MS-related spasticity, specific severity and treatment-history conditions, and specialist supervision. The wider private route still depends on records, previous treatments, risks and specialist assessment.
What if my main issue is pain, not spasticity?
MS pain needs proper clinical assessment. NICE’s cannabis-based medicine recommendation for MS spasticity does not automatically apply to pain. Chronic pain has its own NICE evidence boundary.
Can this guide tell me what to ask for?
It can help you understand the guidance and prepare questions. It does not recommend a product, dose, route, clinic, pharmacy or legal decision. Those decisions belong with an appropriate clinician or specialist prescriber.
Sources
- NHS. Medical cannabis. https://www.nhs.uk/medicines/medical-cannabis/
- NHS. Multiple sclerosis. https://www.nhs.uk/conditions/multiple-sclerosis/
- NICE. Cannabis-based medicinal products: recommendations, NG144. https://www.nice.org.uk/guidance/ng144/chapter/recommendations
- NICE. Multiple sclerosis in adults: recommendations, NG220. https://www.nice.org.uk/guidance/ng220/chapter/Recommendations
- MS Society. Cannabis treatments and therapies for MS. https://www.mssociety.org.uk/living-with-ms/treatments-and-therapies/cannabis
- MS Society. Sativex. https://www.mssociety.org.uk/living-with-ms/treatments-and-therapies/cannabis/sativex
- NHS England. Cannabis-based products for medicinal use. https://www.england.nhs.uk/long-read/cannabis-based-products-for-medicinal-use-cbpms/
- GMC. Information for doctors on cannabis-based products for medicinal use. https://www.gmc-uk.org/professional-standards/learning-materials/information-for-doctors-on-cannabis-based-products-for-medicinal-use
